目的:研究P73、CD59、MMP-19在上皮性卵巢癌及交界性肿瘤中的表达,探讨上述标记物在卵巢上皮性肿瘤发病机制上的作用。方法:取87例卵巢癌、27例交界性肿瘤,分别制成40点的12块组织芯片,用免疫组织化学的方法检测组织芯片中P73、CD59、MMP-19的表达情况,并收集卵巢癌病例的临床病理资料分析其与这些蛋白表达的关系。结果:卵巢癌与交界性肿瘤组中P73的表达有显著性差异(Z=-3.203,P=0.001),CD59、MMP-19的表达无差异;卵巢癌组P73、CD59、MMP-19的阳性表达率分别为46.0%(40/87)、83.9%(73/87)、83.9%(73/87);交界性肿瘤组P73、CD59、MMP-19的阳性表达率分别为70.4%(19/27)、81.5%(22/27)、85.2%(23/27),两组中不同组织类型肿瘤在P73的表达率上均存在明显差异(卵巢癌组:χ^2=19.144,P=0.001;交界性肿瘤组χ^2=7.849,P=0.013)。结论:上皮性卵巢癌中P73的表达明显低于交界性肿瘤,其表达情况与组织类型有关,提示P73作为肿瘤抑制基因,它的丢失可能与卵巢癌的发病密切相关。
Objective :To study the expression of p73 ,CD59 ,MMP - 19 in the epithelial ovarian carcinoma and epithelial borderline tumors, and to investigate their use in pathogenesis of ovarian cancer and epithelial borderline tumors. Methods:87 cases of ovarian carcinomas and 27 cases of ovarian borderline tumors in People's Hospital, Peking University were reviewed retrospectively. Immunohistochemical study for p^73 、 CD59, MMP - 19 was performed in all these cases. Results: There were significant difference in expression for p^73 between borderline tumors and carcinomas ( Z = - 3. 203,P = 0. 001 ), But There were no difference in expression for CD59, MMP - 19; Overexpression of p73 ,CD59 ,MMP - 19 was observed in 46. 0% (40/87) ,83.9% (73/87) ,83.9% (73/87) of ovarian carcinomas, Overexpression of p73, CD59 ,MMP - 19 was observed in 70. 4% (19/27) ,81.5% (22/27) ,85.2% (23/27) of ovarian borderline tumors. There were significant difference in expression for p73 among different histological types of borderline tumors and carcinomas( ovarian carcinomas :X^2 = 19. 144 ,P = 0. 001 ; ovarian borderline tumors X^2 = 7. 849, P = 0. 013 ). Conclusions : Epithelial ovarian borderline tumors are distinct from ovarian cancer in expression of p73, The expression of p73 in ovarian carcinoma was correlated with the histological types, The p^73 may be an important molecular change and play a certain role in malignant progression of ovarian tumor from borderline tumors to carcinoma.